News | July 13, 2012

GE, VPDiagnostics Collaborate on MRI of Carotid Artery Atherosclerosis Imaging, Plaque Analysis

New collaboration aims to improve research and clinical development in vulnerable plaque assessment

MRI-PlaqueView's 3-D visualization of carotid plaque morphology and composition.


July 13, 2012 — GE Healthcare and VPDiagnostics Inc. jointly announced today their co-marketing agreement for the VPDiagnostics’ MRI-PlaqueView software for carotid artery atherosclerosis analysis. The MRI-PlaqueView software is compatible with carotid magnetic resonance imaging (MRI) data acquired from GE 3.0T MRI systems (HDxt and Discovery MR750). The collaboration will aim to develop optimized carotid imaging protocols and future co-developments on new techniques.

Carotid atherosclerosis may be responsible for as much as one-third of all strokes. To better gauge risk of stroke from carotid atherosclerosis, clinicians are beginning to look beyond traditional risk factors such as carotid artery narrowing (stenosis) to identify high-risk features of the atherosclerotic plaque itself. The GE 3.0T MRI systems and dedicated carotid coil enables high-resolution multi-contrast imaging of carotid lumens, vessel walls and atherosclerotic plaques, while the MRI PlaqueView software from VPDiagnostics provides analysis of these images to delineate various plaque components such as vessel wall, calcified and soft plaques, and help provide a better assessment of the plaque characteristics.

For more information: www.gehealthcare.com 

 


Related Content

News | Contrast Media

August 17, 2023 — University of Missouri School of Medicine neurologist Adnan Qureshi, MD recently led a study that ...

Home August 17, 2023
Home
News | Contrast Media

July 3, 2023 — According to an accepted manuscript published in ARRS’ own American Journal of Roentgenology (AJR) ...

Home July 03, 2023
Home
News | Contrast Media

May 11, 2021 — The American Institute of Ultrasound in Medicine (AIUM) and the American Society of Echocardiography (ASE ...

Home May 11, 2021
Home
Technology | Contrast Media

July 15, 2019 — The U.S. Food and Drug Administration (FDA) has approved Gadavist injection for use in cardiac magnetic ...

Home July 15, 2019
Home
Videos | Contrast Media

Sharon Mulvagh, M.D., FASE, FACC, FRCPC, professor of medicine, division of cardiology, Dalhousie University, Halifax ...

Home June 28, 2019
Home
Feature | Contrast Media | Dave Fornell, Editor

Iodine-based contrast agents used in computed tomography (CT) and catheter-based angiography have been implicated as a ...

Home May 31, 2019
Home
News | Contrast Media

May 9, 2019 — Osprey Medical announced the launch of DyeMINISH, a global patient registry to evaluate the ongoing safety ...

Home May 09, 2019
Home
News | Contrast Media

November 30, 2018 — VigiLanz and Cincinnati Children’s Hospital Medical Center recently announced a collaboration that ...

Home November 30, 2018
Home
News | Contrast Media

In February 2018, a workshop was held at the National Institutes of Health (NIH) in Bethesda, Maryland, to explore ...

Home September 12, 2018
Home
News | Contrast Media

January 19, 2018 — Ligand Pharmaceuticals Inc. announced initiation of a program to develop contrast agents with reduced ...

Home January 19, 2018
Home
Subscribe Now